Life Sciences

  • November 28, 2023

    Insurers Escape Allergy Treatment Groups' Antitrust Claims

    A Louisiana federal court has tossed antitrust claims from allergy testing and immunotherapy outfits against Blue Cross Blue Shield of Louisiana and other insurers after finding a lack of evidence showing a conspiracy to push the groups out of the market.

  • November 28, 2023

    Biotech Co.'s Counterclaims Against Ex-Exec Trimmed

    A California federal judge has tossed a Colorado biotechnology company's counterclaims alleging fraud and negligent misrepresentation by a co-founder and technology chief of another firm it acquired for $35 million in 2022, but allowed the biotech's bid for declaratory relief regarding the executive's exit from the company to move forward.

  • November 28, 2023

    UCLA Study Finds Calif. Teens Can't Get Plan B At Pharmacies

    Pharmacies in California are denying adolescents emergency contraception like Plan B despite a state law giving minors access to that treatment, according to a new study released by a research center at the UCLA School of Law.

  • November 28, 2023

    Drugmakers Argue Double Patenting Ruling Defies Congress

    AbbVie, Merck, Johnson & Johnson, AstraZeneca, Novartis and other big-name pharmaceutical companies are urging the full Federal Circuit to reconsider a patent invalidation that they say placed a judicially made rule above law set by Congress.

  • November 28, 2023

    Group Says Doctor COVID-19 Disinformation Suit Isn't Moot

    The New Civil Liberties Alliance has told a California federal court that a suit over a California law punishing medical professionals for COVID-19 disinformation should move forward despite a newly enacted law repealing it because doctors still suffered damages and the state is sidestepping a potentially adverse ruling.

  • November 28, 2023

    Mich. Health Dept. Asks 6th Circ. To Back Baby Blood Program

    Michigan health officials urged the Sixth Circuit Monday to reverse a ruling that dismantled its newborn blood-screening program, calling that program a "paragon of good government."

  • November 28, 2023

    Daiichi Awarded $46M Fees In Cancer Drug Patent Arbitration

    Japanese drugmaker Daiichi Sankyo Ltd. has scored nearly $46 million in fees and costs in an arbitration initiated by rival Seagen in the companies' patent dispute over cancer drug technology after the arbitrator found that the U.S. biotech company did not file its infringement claims within the six-year statute of limitations.

  • November 28, 2023

    Sanctioned Wholesaler Wants Abbott Labs Out Of Her Trust

    A medical wholesaler executive's wife is trying to stop Abbott Laboratories from reaching into her trust in order to satisfy a $33 million judgment against the pair that came after they were found to have engaged in discovery fraud.

  • November 28, 2023

    Rep. Eshoo On Retiring: 'Health Care Has Been My North Star'

    Over three decades on Capitol Hill and five presidential administrations, Rep. Anna G. Eshoo has left a deep mark on American health care and the pharmaceutical industry. As she prepares to retire, the California Democrat spoke with Law360 about what sparked her interest in health care reform, the battle to pass the Affordable Care Act and what she hasn't been able to accomplish in her long career.

  • November 28, 2023

    USPTO Wants Antibody Patent Case Sent Back For Review

    The U.S. Patent and Trademark Office says the Federal Circuit should terminate Xencor Inc.'s appeal of a Patent Trial and Appeal Board decision that backed an examiner's denial of an application for a patent on antibodies that can be used in autoimmune disease treatments.

  • November 28, 2023

    Fajr Capital-Led Consortium Paying $1B For Aster's Gulf Biz

    An Allen & Overy-advised consortium led by Dubai-based Fajr Capital has agreed to acquire 65% of hospital chain Aster DM Healthcare's Gulf Cooperation Council business for $1 billion, Fajr said Tuesday. 

  • November 28, 2023

    Sens. Question Anesthesia Co.'s 'Monopolistic' Model

    Sens. Elizabeth Warren and Richard Blumenthal have asked the CEO of U.S. Anesthesia Partners to rethink its "monopolistic business model" and its use of noncompete agreements among doctors.

  • November 28, 2023

    Law Firm Leaders Cautiously Optimistic Heading Into 2024

    Major U.S. law firms are steadfast in their commitment to the pursuit of further growth despite ongoing economic uncertainty. Here’s what the leaders of four Leaderboard firms have to say about how the legal industry is preparing for next year.

  • November 28, 2023

    The 2023 Law360 Pulse Leaderboard

    Check out the Law360 Pulse Leaderboard to see which first-in-class firms made the list this year.

  • November 28, 2023

    Bristol Myers Strikes Up To $2.3B Avidity Cardio Partnership

    Bristol Myers Squibb has struck a research partnership with Avidity Biosciences Inc. that could see the biopharmaceutical giant funnel up to $2.3 billion into the discovery, development and commercialization of certain treatments for cardiovascular disease, Avidity said Tuesday. 

  • November 27, 2023

    Levi, Pomerantz Seek To Lead Insulin Pump Co. Investor Suit

    Levi & Korsinsky LLP and Pomerantz LLP want to represent a proposed class of investors in a suit alleging insulin pump maker Tandem Diabetes Care Inc. and its executives misled the public about the company's growth prospects for the year amid inflation and an uptick in competition.

  • November 27, 2023

    Amicus Groups Tell High Court To End Chevron Deference

    Six groups, including the Ohio Chamber of Commerce and several former state supreme court judges, filed friend-of-the-court briefs on Monday urging the U.S. Supreme Court to overturn a decades-old legal doctrine stating that courts must defer to federal agencies' interpretation of ambiguous laws.

  • November 27, 2023

    HHS' OIG Finds Low Risk Of Misuse For Opioid Treatment Drug

    The federal government is formulating a plan to expand access to medication for opioid abuse following an analysis published Monday that shows low risk for misuse of the drug buprenorphine.

  • November 27, 2023

    Regeneron False Claims Act Case Paused Amid Appeal

    A Massachusetts federal judge has pressed pause on a False Claims Act case against Regeneron while the First Circuit decides whether his interpretation of the law's causation standard or that of his colleague in the same courthouse is correct.

  • November 27, 2023

    PTAB Denies Review Of Univ. Of Texas System Cancer Patent

    The Patent Trial and Appeal Board has denied a petition by biotechnology company Microbiotica seeking post-grant review of a cancer treatment patent held by the University of Texas System.

  • November 27, 2023

    Arthrex Gets PTAB To Strike Down More P Tech Patents

    The Patent Trial and Appeal Board has again sided with medical device company Arthrex Inc. in its patent dispute with P Tech LLC, finding as obvious two additional P Tech surgery patents that are being litigated in federal district court.

  • November 27, 2023

    Teva, Eli Lilly Call Off Infringement Suit Over Migraine Drug

    Teva Pharmaceuticals International GmbH has moved in Massachusetts federal court to permanently drop an infringement case against Eli Lilly and Co. over a migraine drug — an action taken after the Patent Trial and Appeal Board found two patents related to the drug and its use invalid.

  • November 27, 2023

    Longhorn Vaccines Urges Vidal To Ax PTAB Sanctions Order

    Longhorn Vaccines & Diagnostics LLC says the U.S. Patent and Trademark Office director should throw out a sanctions order against it, given as punishment for when a patent owner withholds key evidence from the Patent Trial and Appeal Board.

  • November 27, 2023

    FDA Quits Global Med Device Regulatory Group

    The U.S. Food and Drug Administration has withdrawn from the medical device regulatory working group Global Harmonization Working Party just two years after joining in 2021, saying the group lacked the effort to work with other international regulatory authorities.

  • November 27, 2023

    Indian Glycine Co.'s Waffling Justifies Penalty Duties

    The U.S. Court of International Trade stood by the penalty tariffs the U.S. Department of Commerce issued to an Indian glycine producer that offered officials contradictory evidence on whether it had ties with other glycine companies in India.

Expert Analysis

  • Kochava Ruling May Hint At Next Privacy Class Action Wave

    Author Photo

    The Southern District of California's recent ruling in Greenley v. Kochava and increasing complaints alleging that a consumer website is an illegal “pen register” due to the use of third-party marketing software tools foreshadow a new theory of liability for plaintiffs in privacy litigation, say attorneys at Crowell & Moring.

  • Forecasting The Impact Of High Court Debit Card Rule Case

    Author Photo

    John Delionado and Aidan Gross at Hunton consider how the U.S. Supreme Court's forthcoming ruling in a retailer's suit challenging a Federal Reserve rule on debit card swipe fees could affect agency regulations both new and old, as well as the businesses that might seek to challenge them.

  • Series

    ESG Around The World: Mexico

    Author Photo

    ESG has yet to become part of the DNA of the Mexican business model, but huge strides are being made in that direction, as more stakeholders demand that companies adopt, at the least, a modicum of sustainability commitments and demonstrate how they will meet them, says Carlos Escoto at Galicia Abogados.

  • Opinion

    FDA And Companies Must Move Quickly On Drug Recalls

    Author Photo

    When a drug doesn't work as promised — whether it causes harm, like eyedrops recalled last month by the U.S. Food and Drug Administration, or is merely useless, like a widely used decongestant ingredient recently acknowledged by the agency to be ineffective — the public must be notified in a timely manner, says Vineet Dubey at Custodio & Dubey.

  • The Case For Post-Bar Clerk Training Programs At Law Firms

    Author Photo

    In today's competitive legal hiring market, an intentionally designed training program for law school graduates awaiting bar admission can be an effective way of creating a pipeline of qualified candidates, says Brent Daub at Gilson Daub.

  • Opinion

    A Telecom Attorney's Defense Of The Chevron Doctrine

    Author Photo

    The Chevron doctrine, which requires judicial deference to federal regulators, is under attack in two U.S. Supreme Court cases — and while most telecom attorneys likely agree that the Federal Communications Commission is guilty of overrelying on it, the problem is not the doctrine itself, says Carl Northrop at Telecommunications Law Professionals.

  • What's At Stake In Bystolic 'Side Deals' Litigation

    Author Photo

    In re: Bystolic Antitrust Litigation, which has oral argument set for next month, will likely shed light on how the U.S. Court of Appeals for the Second Circuit views side deals, and could create a circuit split in pleading standards for reverse payment cases, say attorneys at Axinn.

  • 2 HHS Warnings Highlight Anti-Kickback Risks For Physicians

    Author Photo

    Two recent advisory opinions issued by the U.S. Department of Health and Human Services' Office of Inspector General involve different scenarios and rationales, but together they illustrate the OIG's focus on and disapproval of contractual joint ventures and other revenue-maximizing physician arrangements, say Robert Threlkeld and Elliott Coward at Morris Manning.

  • Attorneys Have An Ethical Duty To Protect The Judiciary

    Author Photo

    The tenor of public disagreement and debate has become increasingly hostile against judges, and though the legislative branch is trying to ameliorate this safety gap, lawyers have a moral imperative and professional requirement to stand with judges in defusing attacks against them and their rulings, says Deborah Winokur at Cozen O'Connor.

  • Cross-Market Implications In FTC's Anesthesia Complaint

    Author Photo

    The Federal Trade Commission's recent complaint against a private equity firm's acquisition of anesthesiology practices highlights the controversial issue of cross-market harm in health care provider mergers, and could provide important insights into how a court may view such theories of harm, say Christopher Lau and Dina Older Aguilar at Cornerstone Research.

  • FTC Orange Book Move Signals New Pharma Patent Scrutiny

    Author Photo

    The Federal Trade Commission's recent dispute against improper listing of drug patents in the U.S. Food and Drug Administration's Orange Book indicates heightened surveillance of the pharmaceutical industry, particularly where competition-related consequences of patent or regulatory processes are concerned, say attorneys at Fenwick.

  • AI Can Help Lawyers Overcome The Programming Barrier

    Author Photo

    Legal professionals without programming expertise can use generative artificial intelligence to harness the power of automation and other technology solutions to streamline their work, without the steep learning curve traditionally associated with coding, says George Zalepa at Greenberg Traurig.

  • How Legal Teams Can Prep For Life Sciences' Tech Revolution

    Author Photo

    The life sciences and health care industries are uniquely positioned to take advantage of new efficiencies created by cloud computing and generative artificial intelligence, but the sensitivity of their data also demands careful navigation of an expanding legislative and regulatory landscape, say Kristi Gedid, Zack Laplante and Lisa LaMotta at Ernst & Young.

  • Preparing Law Students For A New, AI-Assisted Legal World

    Author Photo

    As artificial intelligence rapidly transforms the legal landscape, law schools must integrate technology and curricula that address AI’s innate challenges — from ethics to data security — to help students stay ahead of the curve, say Daniel Garrie at Law & Forensics, Ryan Abbott at JAMS and Karen Silverman at Cantellus Group.

  • Series

    ESG Around The World: South Korea

    Author Photo

    Numerous ESG trends have materialized in South Korea in the past three years, with impacts ranging from greenwashing prevention and carbon neutrality measures to workplace harassment and board diversity initiatives, say Chang Wook Min and Hyun Chan Jung at Jipyong.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!